Greenwich Wealth Management LLC grew its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 0.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 123,704 shares of the biopharmaceutical company’s stock after purchasing an additional 461 shares during the period. Pfizer comprises approximately 0.6% of Greenwich Wealth Management LLC’s investment portfolio, making the stock its 24th largest holding. Greenwich Wealth Management LLC’s holdings in Pfizer were worth $5,047,000 at the end of the most recent reporting period.
Several other hedge funds have also bought and sold shares of PFE. Moneta Group Investment Advisors LLC boosted its position in Pfizer by 89,592.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares in the last quarter. Norges Bank purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $3,150,472,000. Morgan Stanley lifted its position in shares of Pfizer by 10.3% during the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock valued at $4,073,547,000 after buying an additional 7,419,929 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 13.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock valued at $3,097,341,000 after buying an additional 6,972,650 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of Pfizer during the 1st quarter valued at approximately $311,238,000. Hedge funds and other institutional investors own 67.80% of the company’s stock.
Pfizer Stock Down 0.3 %
Shares of PFE opened at $35.53 on Friday. Pfizer Inc. has a 52-week low of $35.35 and a 52-week high of $54.93. The company has a market capitalization of $200.58 billion, a PE ratio of 6.99, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. The stock has a fifty day simple moving average of $38.03 and a two-hundred day simple moving average of $41.57. The company has a quick ratio of 1.11, a current ratio of 1.37 and a debt-to-equity ratio of 0.31.
Pfizer Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 5th. Investors of record on Friday, July 28th will be given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 4.62%. The ex-dividend date of this dividend is Thursday, July 27th. Pfizer’s payout ratio is 32.28%.
Analyst Ratings Changes
A number of research analysts have recently issued reports on the company. Barclays decreased their target price on Pfizer from $43.00 to $40.00 in a research report on Wednesday, May 3rd. UBS Group decreased their target price on Pfizer from $41.00 to $39.00 in a research report on Friday, May 5th. Bank of America decreased their target price on Pfizer from $50.00 to $45.00 and set a “neutral” rating on the stock in a research report on Friday, April 21st. Wells Fargo & Company reduced their price objective on Pfizer from $50.00 to $44.00 and set an “equal weight” rating for the company in a research note on Friday, March 17th. Finally, Credit Suisse Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $47.00 to $40.00 in a research note on Thursday, June 29th. Eleven research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Pfizer has an average rating of “Hold” and an average target price of $46.67.
Insider Buying and Selling
In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction that occurred on Monday, May 8th. The stock was purchased at an average cost of $38.58 per share, with a total value of $38,580.00. Following the transaction, the director now owns 6,000 shares of the company’s stock, valued at $231,480. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.05% of the company’s stock.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
- Five stocks we like better than Pfizer
- MarketBeat Week in Review – 7/3 – 7/7
- Pfizer Just Invested $25 million In This Biotech
- Cracks In The Labor Market? Not Yet, But They’re Coming
- Levi’s: Buy On The Dip Or Downtrend In Play?
- Who Wins And Who Loses With China’s Metal Restrictions
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
